MedTrace Logo

Postpartum ASA and NT-proBNP

NCT05889468 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 114

Last updated 2025-06-04

Study results available
· View outcomes & findings →

Summary

This study is a double-blinded randomized-controlled trial in which patients will be randomized to 81 mg of aspirin or placebo to be continued for 6 weeks' postpartum. The purpose of this study is to compare NT-proBNP levels at the 4-6 week postpartum visit between groups. There is currently no data on the maternal health effects associated with continuation of low-dose aspirin in the postpartum period. This study aims to fill a gap in the knowledge regarding the utility of low-dose aspirin following delivery.

Conditions

  • Blood Pressure

Interventions

DRUG

Aspirin 81Mg Ec Tab

Participant may be provided with a 6-week supply of 81 mg of aspirin prior to discharge from the delivery admission.

DRUG

Placebo

Participant may be provided with a 6-week supply of placebo to discharge from the delivery admission.

Sponsors & Collaborators

Principal Investigators

  • Brenna Hughes, MD · Duke University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-07-01
Primary Completion
2024-05-21
Completion
2024-05-21
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05889468 on ClinicalTrials.gov